Hutchison China Meditech Ltd., or Chi-Med, of Hong Kong, reported that data from a recent phase I dose escalation study of single and multiple doses of its spleen tyrosine kinase, HMPL-523, showed all doses to be generally safe and well tolerated. A multiple-dose regimen of 300 mg or less of HMPL-523, administered once daily, was recommended for future phase II trials of the candidate in autoimmune diseases.